Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 7
1991 9
1992 8
1993 15
1994 21
1995 28
1996 33
1997 29
1998 52
1999 39
2000 33
2001 20
2002 12
2003 16
2004 14
2005 17
2006 11
2007 18
2008 11
2009 19
2010 12
2011 11
2012 12
2013 11
2014 14
2015 13
2016 13
2017 5
2018 7
2019 10
2020 4
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

497 results
Results by year
Filters applied: . Clear all
Page 1
Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S. Saito M, et al. Lancet Oncol. 2009 Feb;10(2):115-24. doi: 10.1016/S1470-2045(08)70313-9. Epub 2009 Jan 8. Lancet Oncol. 2009. PMID: 19135415 Clinical Trial.
FINDINGS: 1114 patients were included in the efficacy analyses: 555 patients in the palonosetron group and 559 patients in the granisetron group. 418 of 555 patients (75.3%) in the palonosetron group had complete response during the acute phase compared with 410 of 559 pat …
FINDINGS: 1114 patients were included in the efficacy analyses: 555 patients in the palonosetron group and 559 patients in the granisetro
Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.
Navari R, Gandara D, Hesketh P, Hall S, Mailliard J, Ritter H, Friedman C, Fitts D. Navari R, et al. J Clin Oncol. 1995 May;13(5):1242-8. doi: 10.1200/JCO.1995.13.5.1242. J Clin Oncol. 1995. PMID: 7738628 Clinical Trial.
Granisetron was administered as a single dose of 10 or 40 micrograms/kg before the start of chemotherapy. ...Total control (no vomiting, no retching, no nausea, and no use of rescue) was attained by 38%, 41%, and 39% of all patients who received granisetron 10 micro
Granisetron was administered as a single dose of 10 or 40 micrograms/kg before the start of chemotherapy. ...Total control (no vomiti
Transdermal granisetron.
Duggan ST, Curran MP. Duggan ST, et al. Drugs. 2009;69(18):2597-605. doi: 10.2165/11202780-000000000-00000. Drugs. 2009. PMID: 19943709 Review.
Granisetron is a highly selective serotonin 5-HT(3) receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. The transdermal granisetron system delivers continuous granisetron (3.1 mg/day) into the systemic circulation (via passive
Granisetron is a highly selective serotonin 5-HT(3) receptor antagonist for the prevention of chemotherapy-induced nausea and vomitin
The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial.
Yu Z, Liu W, Wang L, Liang H, Huang Y, Si X, Zhang H, Liu D, Zhang H. Yu Z, et al. Support Care Cancer. 2009 Jan;17(1):99-102. doi: 10.1007/s00520-008-0503-4. Epub 2008 Sep 30. Support Care Cancer. 2009. PMID: 18825421 Clinical Trial.
CR rates for acute CIV were 82.69% for palonosetron and 72.12% for granisetron, which demonstrated that palonosetron was not inferior to granisetron in preventing acute CIV. Comparisons of CR rates for delayed CIV yielded no statistical difference between palonosetr …
CR rates for acute CIV were 82.69% for palonosetron and 72.12% for granisetron, which demonstrated that palonosetron was not inferior …
Randomized clinical trial of granisetron, droperidol and metoclopramide for the treatment of nausea and vomiting after laparoscopic cholecystectomy.
Fujii Y, Tanaka H, Kawasaki T. Fujii Y, et al. Br J Surg. 2000 Mar;87(3):285-8. doi: 10.1046/j.1365-2168.2000.01393.x. Br J Surg. 2000. PMID: 10718795 Retracted. Clinical Trial.
BACKGROUND: Patients undergoing laparoscopic cholecystectomy (LC) may be especially at risk of experiencing postoperative nausea and vomiting (PONV). This study was undertaken to evaluate the efficacy of granisetron, droperidol and metoclopramide for the treatment of PONV …
BACKGROUND: Patients undergoing laparoscopic cholecystectomy (LC) may be especially at risk of experiencing postoperative nausea and vomitin …
Pharmacokinetics and safety of transdermal and oral granisetron in healthy Chinese subjects: An open-label, randomized, crossover study.
Chen R, Chen X, Wang H, Zhong W, Oh ES, Park MS, Kumagai Y, Zhou L, Nagahama F, Hu P. Chen R, et al. Int J Clin Pharmacol Ther. 2019 Jan;57(1):24-31. doi: 10.5414/CP203327. Int J Clin Pharmacol Ther. 2019. PMID: 30336808 Clinical Trial.
MATERIALS AND METHODS: A single 34.3 mg/52 cm(2) transdermal delivery patch of granisetron and the 1-mg tablet of granisetron were dosed to subjects in an open-label, randomized, crossover study. ...CONCLUSION: The C(avg) values determined through TD and OA were equ …
MATERIALS AND METHODS: A single 34.3 mg/52 cm(2) transdermal delivery patch of granisetron and the 1-mg tablet of granisetron
Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial.
Iihara H, Shimokawa M, Gomyo T, Fujita Y, Yoshida T, Funaguchi N, Minato K, Kaito D, Osawa T, Yamada M, Hirose C, Suzuki A, Ohno Y. Iihara H, et al. BMJ Open. 2019 Jul 4;9(7):e028056. doi: 10.1136/bmjopen-2018-028056. BMJ Open. 2019. PMID: 31278102 Free PMC article. Clinical Trial.
This phase II trial aimed at evaluating the efficacy and safety of 5 mg OLZ plus granisetron (GRN) and DEX in CBDCA combination therapy with area under curve (AUC) 5 mg/mL/min for the prevention of nausea and vomiting in patients with thoracic cancer. ...
This phase II trial aimed at evaluating the efficacy and safety of 5 mg OLZ plus granisetron (GRN) and DEX in CBDCA combination thera …
A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide.
Matsumoto K, Takahashi M, Sato K, Osaki A, Takano T, Naito Y, Matsuura K, Aogi K, Fujiwara K, Tamura K, Baba M, Tokunaga S, Hirano G, Imoto S, Miyazaki C, Yanagihara K, Imamura CK, Chiba Y, Saeki T. Matsumoto K, et al. Cancer Med. 2020 May;9(10):3319-3327. doi: 10.1002/cam4.2979. Epub 2020 Mar 13. Cancer Med. 2020. PMID: 32168551 Free PMC article. Clinical Trial.
RESULTS: From December 2012 to October 2014, 326 patients were treated and evaluated (164/162 evaluable patients in granisetron/palonosetron arm, respectively). The CR during the delayed phase was 60.4% in the granisetron regimen and 62.3% in the palonosetron regime …
RESULTS: From December 2012 to October 2014, 326 patients were treated and evaluated (164/162 evaluable patients in granisetron/palon …
Granisetron and ondansetron for chemotherapy-related nausea and vomiting.
Zeidman A, Ben Dayan D, Ben Zion T, Kaufman O, Cohen AM, Mittelman M. Zeidman A, et al. Haematologia (Budap). 1998;29(1):25-31. Haematologia (Budap). 1998. PMID: 9704254 Clinical Trial.
The efficacy of granisetron and ondansetron, two serotonin antagonists, as antiemetic agents was studied and compared in the first 24 h follow, by chemotherapy administration. ...In group A (adriamycin-cisplatinum) only 7 patients (22%) reported vomiting, 5 (33%) on ondans …
The efficacy of granisetron and ondansetron, two serotonin antagonists, as antiemetic agents was studied and compared in the first 24 …
Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
A Mahrous M, A El-Azab G, A Tawfik H. A Mahrous M, et al. Cancer Chemother Pharmacol. 2021 Jul;88(1):121-129. doi: 10.1007/s00280-021-04257-7. Epub 2021 Apr 9. Cancer Chemother Pharmacol. 2021. PMID: 33835230 Clinical Trial.
This study aimed to evaluate the antiemetic efficacy of palonosetron (PALO) over granisetron (GRA) in combination with dexamethasone for multiple highly emetogenic chemotherapy drugs (HEC), especially in chemotherapy regimens in Egyptian breast cancer patients and cisplati …
This study aimed to evaluate the antiemetic efficacy of palonosetron (PALO) over granisetron (GRA) in combination with dexamethasone …
497 results